Provided by Tiger Trade Technology Pte. Ltd.

60 degrees pharmaceuticals, Inc.

2.28
-0.0753-3.19%
Volume:31.93K
Turnover:74.28K
Market Cap:2.94M
PE:-0.12
High:2.42
Open:2.42
Low:2.28
Close:2.36
52wk High:17.68
52wk Low:1.36
Shares:1.29M
Float Shares:1.14M
Volume Ratio:1.12
T/O Rate:2.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.2914
EPS(LYR):-74.1816
ROE:-154.77%
ROA:-70.04%
PB:-0.57
PE(LYR):-0.03

Loading ...

BRIEF-60 Degrees Pharmaceuticals, Inc. Announces Approval Of Reverse Stock Split Ratio

Reuters
·
Jan 15

60 Degrees Pharmaceuticals Announces 1-for-4 Reverse Stock Split

Reuters
·
Jan 15

60 Degrees Pharma outlines growth strategy in investor webinar

TIPRANKS
·
Jan 08

60 Degrees Pharmaceuticals Launches B-Free Study to Evaluate Tafenoquine for Chronic Babesiosis Fatigue

Reuters
·
Dec 29, 2025

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting With Chronic Fatigue in Peer-Reviewed, Sponsored Study at Nc State

THOMSON REUTERS
·
Dec 29, 2025

Geoffrey S. Dow, President and CEO, Acquires Common Shares of 60 Degrees Pharmaceuticals Inc

Reuters
·
Dec 17, 2025

Geoffrey S. Dow, President and CEO, Acquires Common Shares of 60 Degrees Pharmaceuticals Inc

Reuters
·
Dec 12, 2025

BRIEF-60 Degrees Pharmaceuticals Announces Expansion Of Arakoda Sales And Marketing In 2026

Reuters
·
Dec 11, 2025

60 Degrees Pharmaceuticals Announces Expansion of Arakoda® Sales and Marketing in 2026

THOMSON REUTERS
·
Dec 11, 2025

60 Degrees Pharmaceuticals Inc - to Add Clinical Sites for Babesiosis Trials

THOMSON REUTERS
·
Dec 11, 2025

60 Degrees Pharm Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Nov 28, 2025

BRIEF-60 Degrees Pharmaceuticals Announces Clinical Site Now Open For Patient Enrollment

Reuters
·
Nov 21, 2025

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

GlobeNewswire
·
Nov 21, 2025

60 Degrees Pharmaceuticals Faces Financial Challenges Amid Growth Efforts

TIPRANKS
·
Nov 18, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

TIPRANKS
·
Nov 17, 2025

60 Degrees Pharm Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
Nov 14, 2025

60 Degrees Q3 EPS $(0.66) Beats $(1.21) Estimate, Sales $437.602K Beat $400.000K Estimate

Benzinga
·
Nov 14, 2025

60 Degrees Pharmaceuticals Q3 Operating Expenses USD 2.32 Million

THOMSON REUTERS
·
Nov 14, 2025

60 Degrees Pharmaceuticals Q3 Net Income USD -2.44 Million

THOMSON REUTERS
·
Nov 14, 2025

60 Degrees Pharmaceuticals Q3 EPS USD -0.66

THOMSON REUTERS
·
Nov 14, 2025